Massive stroke drug study shows promise in routine care
NCT ID NCT06707987
First seen Jan 05, 2026 · Last updated May 21, 2026 · Updated 24 times
Summary
This study tested a clot-busting drug called non-immunogenic staphylokinase in over 23,000 people who had an acute ischemic stroke. The goal was to see how safe and effective the drug is in everyday hospital settings. Patients received the drug within 4.5 hours of their first symptoms, and doctors measured their recovery 90 days later using a scale that tracks disability.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Federal Brain and Neurotechnology Center
Moscow, 117513, Russia
Conditions
Explore the condition pages connected to this study.